Fenbid

Fenbid developed as a China-market consumer-health brand focused on over-the-counter analgesia and antipyresis. Its principal identity is linked to ibuprofen sustained-release capsules, a formulation intended to extend the duration between doses while addressing common short-term pain and fever indications covered by the approved label. The brand became recognizable through pharmacy and retail distribution, consumer-facing packaging, and the broader growth of China's self-medication market. The supplied reference material does not provide a reliable date for the brand's launch, the identity of its original creator, or a complete record of regulatory registrations and product introductions. It also does not establish a definitive manufacturing location or headquarters. These omissions are material because a consumer medicine brand may be marketed through one company, manufactured by another licensed entity, and owned through a wider corporate structure. No such details are therefore inferred here. Fenbid has historically been associated with the China consumer-health activities of GlaxoSmithKline. GSK later separated its consumer-health business into Haleon, but the available material does not conclusively document the legal chain for the Fenbid trademark, the date of any transfer, or the current registrant. The brand should consequently be understood as an OTC product brand with an incompletely documented corporate history rather than automatically equated with either GSK or Haleon. The brand's best-documented product is the ibuprofen sustained-release capsule. Ibuprofen is a non-steroidal anti-inflammatory drug with analgesic, antipyretic, and anti-inflammatory properties. Fenbid's sustained-release presentation is designed for prolonged action, but the appropriate dose, frequency, patient population, and duration of self-treatment depend on the approved Chinese label. The product is not interchangeable with every other ibuprofen preparation, and consumers are expected to follow package instructions and seek medical advice when symptoms persist or warning signs occur. Reference material also associates Fenbid with paracetamol tablets. The evidence available for this dossier does not establish whether that item is a current core product, a historical product, or a product marketed under the brand only in particular channels or registrations. It is listed as a possible associated product but not treated as a fully documented flagship offering. Fenbid remains treated as active because an official brand website is supplied and the brand is identified as an OTC medicine brand. The available sources do not support a detailed account of advertising campaigns, product recalls, lawsuits, scandals, executive appointments, or major corporate decisions. Those areas are left blank rather than supplemented with unverified claims.

A familiar Chinese OTC analgesic brand centered on ibuprofen sustained-release products for temporary relief of common pain and fever.

• Fenbid ibuprofen sustained-release capsulesOTC analgesic and antipyretic

  The brand's principal documented offering is an ibuprofen sustained-release capsule for the temporary relief of pain and fever within the approved indications. The sustained-release dosage form is intended to provide longer-lasting exposure than an immediate-release presentation and is commonly associated with everyday complaints such as headache, toothache, muscular pain, menstrual pain, joint pain, and fever. Exact indications, age limits, dosage, contraindications, and warnings must be taken from the current Chinese product label and package insert.

• Fenbid paracetamol tabletsOTC analgesic and antipyretic

  Paracetamol tablets are identified in the supplied material as a product associated with Fenbid. The available evidence does not establish the product's launch date, current availability, exact registration holder, or whether it remains part of the brand's standard portfolio. It is therefore recorded as an associated product requiring confirmation from current regulatory and brand sources.

1. Fenbid official website